Research and Markets: Global Pulmonary Hypertension Clinical Trials Review Report - H2 2013

Research and Markets (http://www.researchandmarkets.com/research/c2657p/pulmonary) has announced the addition of the "Pulmonary Hypertension Global Clinical Trials Review, H2, 2013" report to their offering.

Pulmonary Hypertension Global Clinical Trials Review, H2 2013 provides data on the Pulmonary Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pulmonary Hypertension . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pulmonary Hypertension .

Scope

• Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
• Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
• Listings of discontinued trials (suspended, withdrawn and terminated)

Top Companies Participating in Pulmonary Hypertension Therapeutics Clinical Trials

• Actelion Ltd
• Pfizer Inc.
• United Therapeutics Corporation
• Bayer AG
• Gilead Sciences, Inc.
• GlaxoSmithKline plc
• Novartis AG
• Eli Lilly and Company
• Lung LLC
• INO Therapeutics, LLC

For more information visit http://www.researchandmarkets.com/research/c2657p/pulmonary

Research and Markets
Laura Wood, Senior Manager
[e-mail]
U.S. Fax: [phone]
Fax (outside U.S.): [phone]
Sector: Cardiovascular